|
Originally published In Press as doi:10.1074/jbc.M203247200 on May 1, 2002
J. Biol. Chem., Vol. 277, Issue 29, 26372-26378, July 19, 2002
Proteinases of the Bone Morphogenetic Protein-1 Family Convert
Procollagen VII to Mature Anchoring Fibril Collagen*
Anke
Rattenholl ,
William N.
Pappano§,
Manuel
Koch¶,
Douglas R.
Keene ,
Karl E.
Kadler**,
Takako
Sasaki ,
Rupert
Timpl ,
Robert E.
Burgeson¶,
Daniel S.
Greenspan§, and
Leena
Bruckner-Tuderman §§
From the Department of Dermatology, University of
Münster, 48149 Münster, Germany, the
§ Departments of Pathology and Laboratory Medicine and
Biomolecular Chemistry, University of Wisconsin,
Madison, Wisconsin 53706, ¶ Cutaneous Biology Research Center,
Massachusetts General Hospital/Harvard Medical School,
Charlestown, Massachusetts 02129, Shriners Hospital for
Children, Portland, Oregon 97201, ** Wellcome Trust
Centre for Cell-Matrix Research, School of Biological Sciences,
University of Manchester, Manchester M139PT, United Kingdom, and
 Max-Planck-Institute for Biochemistry,
82152 Martinsried, Germany
Received for publication, April 5, 2002, and in revised form, April 30, 2002
 |
ABSTRACT |
Collagen VII is the major structural component of
the anchoring fibrils at the dermal-epidermal junction in the skin. It
is secreted by keratinocytes as a precursor, procollagen VII, and processed into mature collagen during polymerization of the anchoring fibrils. We show that bone morphogenetic protein-1 (BMP-1), which exhibits procollagen C-proteinase activity, cleaves the C-terminal propeptide from human procollagen VII. The cleavage occurs at the BMP-1
consensus cleavage site SYAA DTAG within the NC-2 domain. Mammalian tolloid-like (mTLL)-1 and -2, two other proteases of the
astacin enzyme family, were able to process procollagen VII at the same
site in vitro. Immunohistochemical and genetic evidence supported the involvement of these enzymes in cleaving type VII procollagen in vivo. Both BMP-1 and mTLL-1 are expressed in
the skin and in cultured cutaneous cells. A naturally occurring
deletion in the human COL7A1 gene, 8523del14, which is
associated with dystrophic epidermolysis bullosa and eliminates the
BMP-1 consensus sequence, abolished processing of procollagen VII, and
in mutant skin procollagen VII accumulated at the dermal-epidermal
junction. On the other hand, deficiency of BMP-1 in the skin of
knockout mouse embryos did not prevent processing of procollagen VII to mature collagen, suggesting that mTLL-1 and/or mTLL-2 can substitute for BMP-1 in the processing of procollagen VII in
situ.
 |
INTRODUCTION |
Post-translational proteolytic processing of proteins is emerging
as a major regulatory mechanism in biology (1). A wide spectrum of
extracellular matrix molecules is proteolytically cleaved to yield
mature biosynthetic products and to release functionally important
domains or biologically active fragments. Examples are the processing
of procollagens (2-7), proteoglycans (8) or laminins (9, 10) to mature
molecules, the shedding of ectodomains of transmembrane components,
e.g. collagen
XVII1 or syndecans (11), or
the release of biologically active fragments, such as endostatin (12).
Similarly, processing of cell adhesion molecules allows regulation of
cell attachment and migration (13).
Proteinases of the metzincin family (14) are involved in the processing
of many extracellular matrix molecules and function therefore as
important regulators of a variety of biological events (15). The
tolloids are a subfamily of the metzincins, which includes bone
morphogenetic protein
(BMP)-1,2 mammalian tolloid
(mTLD, a product of alternatively spliced mRNA encoded by the same
gene that encodes BMP-1 (16)), and mammalian tolloid-like (mTLL)-1 and
-2 (17, 18). BMP-1 and mTLD exhibit procollagen C-proteinase activity
in that they cleave the C-propeptides from procollagens I-III (19,
20). BMP-1 also cleaves C- and N-propeptides from different chains of
procollagen V (5-7), the prodomains of probiglycan (8) and prolysyl
oxidase (21, 22), chordin (18), and the 3 and 2 chains of laminin
5 (9, 10), thus controlling collagen fibril polymerization (23, 24), proteoglycan maturation, cross-linking of collagens and elastin, dorso-ventral patterning (18, 25), and assembly of the dermal-epidermal junction (26). mTLL-1 appears to have a similar spectrum of substrates
but lower activity than BMP-1 (8, 18, 22). In contrast, so far mTLL-2
has only been shown to process prolysyl oxidase (22).
The dermal-epidermal junction is a highly specialized basement membrane
zone, which ensures the adhesion of the epidermis and the dermis in the
skin. It contains distinct multicomponent aggregates (i.e.
hemidesmosomes, anchoring filaments, and anchoring fibrils), which
interact with each other to provide a tight linkage of the skin layers,
and to mediate cross-talk between the epidermal keratinocytes and
dermal fibroblasts (26). Collagen VII is a major protein of this zone
and the main structural component of the anchoring fibrils.
Keratinocytes synthesize and secrete it into the extracellular space as
a precursor, procollagen VII; during fibril polymerization, a
C-terminal propeptide is proteolytically released (27-29). In normal
human skin, the C-propeptide is completely removed and is not found at
the dermal-epidermal junction. However, in dystrophic epidermolysis
bullosa (DEB), a genetic disease caused by mutations of collagen VII
(30, 31), procollagen can be retained in the skin of the patient,
implying that deficient C-propeptide processing is associated with
functional abnormalities of the anchoring fibrils (32). The importance
of the NC-2 domain for antiparallel dimer formation was recently
demonstrated by Chen et al. (33). However, so far, the
mechanisms of fibrillogenesis of the anchoring fibrils, including the
propeptide cleavage site and the enzyme(s) involved, have remained
elusive. Two lines of evidence point to BMP-1 as the candidate enzyme
for the processing of procollagen VII. First, the NC-2 domain of
procollagen VII contains a BMP-1 consensus sequence motif (8, 34).
Second, laminin 5, a binding ligand of collagen VII at the
dermal-epidermal junction (35), is processed by BMP-1 (9, 36).
The proteolytic cleavage of laminin 5 3 and 2 chains is believed
to regulate the interactions between the laminin molecule and its
ligands, integrin 6 4, laminin 6, and collagen VII. The cleavage of the 2 chain drives deposition of
laminin 5 into the extracellular matrix and sustains cell adhesion
(10). In concert, malignant cells with high migratory activity do not
process laminin 5 completely (37), and in a cylindroma tumor model,
abnormal processing of both chains was associated with striking
structural abnormalities of the basement membrane (38).
The above observations argue for the functional importance of
proteolytic processing of the epidermal adhesion partners laminin 5 and
collagen VII. Here we show that the same enzyme(s) is/are responsible
for the cleavage of both counterparts and postulate that the cleavage
of the keratinocyte-derived laminin 5 and procollagen VII by
fibroblast-derived enzyme(s) presents a mechanism of regulation of the
assembly of the dermal-epidermal junction and an intriguing manifestation of epithelial-mesenchymal interactions.
 |
EXPERIMENTAL PROCEDURES |
Cell Cultures--
Primary human keratinocytes and HaCaT cells
(kindly provided by Norbert E. Fusenig, DKFZ Heidelberg, Germany) were
cultured in keratinocyte growth medium supplemented with 50 µg/ml
bovine pituitary extract and 5 ng/ml recombinant human epidermal growth factor (Invitrogen) as described (39). Primary human skin fibroblasts were grown from skin explants as described (39). Prior to protein analyses, the cells were transferred to a medium without supplements and were grown in the presence of 50 µg/ml L-ascorbic
acid for 48 h.
Protein Extraction--
For extraction of procollagen VII, the
cell layers were washed with cold phosphate-buffered saline and
extracted as described previously (40). Extraction of proteins from
normal or DEB human skin biopsies and normal or Bmp1 /
mouse embryo skin (41) was performed as described (42).
Mutated Procollagen VII--
Mutated procollagen VII was
isolated from cultured keratinocytes of two DEB patients with the
methods described above. COL7A1 mutation analysis was
performed with PCR amplification of all 118 COL7A1 exons
directly from genomic DNA of the patients, followed by heteroduplex
analysis and dideoxynucleotide sequencing, as described previously
(40). Both patients carried the deletion mutation 8523del14 on one
allele of the COL7A1 gene (32, 43). The mutation leads to
in-frame skipping of exon 115, which encodes a sequence of 29 amino
acids containing the BMP-1 cleavage site. On the other
allele, patient 1 carried the known nonsense mutation A425G
(44). Thus, patient 1 was functionally homozygous for the deletion,
i.e. synthesized only homotrimers consisting of deleted
pro (VII) chains. Patient 2 had a glycine substitution mutation
G2009R on the other allele and was thus compound heterozygous for two
different mutations (32).
SDS-PAGE and Immunoblotting--
For SDS-PAGE analysis, proteins
were precipitated with trichloroacetic acid in the presence of
deoxycholic acid (45). Immunoblotting was carried out using standard
techniques. The domain-specific collagen VII antibodies are as follows:
NC1-F3 to the NC-1 domain,3
VII-aff against the triple-helical domain (46), and NC2-7 and NC2-10
against the NC-2 domain of procollagen VII (32). The antibody NC2-7
recognizes epitopes within the propeptide, and therewith only
procollagen VII but not mature collagen VII. The secondary antibody was
peroxidase-conjugated anti-rabbit IgG (Sigma). The signals were
detected with the Renaissance chemiluminescence substrate from
PerkinElmer Life Sciences.
Production of Recombinant Truncated Procollagen VII--
One
µg of total RNA from cultured human foreskin keratinocytes was
reverse-transcribed, and PCR was performed following the manufacturer's instructions (Herculase Enhanced DNA Polymerase, Stratagene, La Jolla, CA). The following fragments of human collagen VII cDNAs were generated and linked together by overlapping PCR: human collagen VII (NM_000094), nucleotides 3237-3965 and
8163-8945. The PCR product was subcloned (Rapid DNA Ligation Kit;
Roche Diagnostics) into the episomal expression vector pCEP-Pu/BM40
(47) (a kind gift from Ernst Pöschl, University of Erlangen,
Germany). For convenience, an octa-His tag followed by a stop codon was
introduced at the 3' end, adjacent to the BamHI site of the
vector. TOP 10 cells (Invitrogen) were transformed with the vector.
Plasmids were isolated from the bacteria (Qiaprep, Qiagen, Hilden,
Germany) and sequenced with gene-specific primers (Thermo Sequenase
Radiolabeled Terminator Cycle Sequencing Kit; U. S. Biochemical
Corp.). 293-EBNA cells (Invitrogen) were transfected (FuGENE, Roche
Diagnostics) with the expression vector and selected after 2 days with
puromycin (Sigma). Transfected 293-EBNA cells were subcloned, and the
clones with the highest protein production were chosen for large scale production. The cells were cultured in the presence of puromycin and of
50 µg/ml ascorbic acid for hydroxylation of prolyl and lysyl residues
within the triple-helical domain. Two liters of supernatant from these
cells were collected and supplemented with 0.5 mM Pefabloc
(AEBSF, Merck). After ammonium sulfate precipitation (45% saturation),
the precipitate was collected by centrifugation and then dialyzed
against binding buffer (200 mM NaCl, 20 mM
Tris-HCl, pH 8). The dialyzed protein was applied onto a
nickel-chelated Sepharose column (Amersham Biosciences AB) and eluted
with binding buffer containing increasing concentrations of imidazole
(10-80 mM imidazole). The protein was dialyzed against
phosphate-buffered saline, and the protein concentration was determined
using the BCA protein assay reagent (Pierce). Rotary shadowing of the
recombinant truncated collagen VII molecules was performed as published
previously (35).
Limited Proteolysis--
For assessment of the domain structure
of the recombinant truncated procollagen VII, 100 µg of protein
(concentration: 1 mg/ml) was subjected to treatment with collagenase or
pepsin as described (48). For deglycosylation, the protein was dialyzed
against 20 mM sodium phosphate, pH 7.2, 20 mM
EDTA, 0.1% (v/v) Triton X-100 and subsequently reduced with 10 µl of
-mercaptoethanol for 10 min at 60 °C prior to digestion with 5 units of N-glycosidase F (Roche Diagnostics) for 18 h
at 37 °C.
Digestion with BMP-1-like Enzymes--
Recombinant human BMP-1,
mTLL-1, and mTLL-2 were prepared as described (18, 36); mTLL-1 and
mTLL-2 carried a FLAG tag. The digestions with 400 ng of enzyme were
performed in 100-200 µl of a buffer containing 50 mM
Tris-HCl, pH 8, 150 mM NaCl, 5 mM
CaCl2, and 1 mM AEBSF for 24 h at
37 °C, unless otherwise stated. When recombinant truncated
procollagen was used as a substrate, 5 µg of the protein were
incubated with the respective protease in the presence of 1 mM AEBSF (Merck), 10 µg/ml soybean trypsin inhibitor (Sigma), and 10 µg/ml leupeptin (Fluka, Buchs,
Switzerland). Reactions were stopped by precipitation of
proteins by trichloroacetic acid in the presence of deoxycholic acid,
and samples were analyzed by SDS-PAGE and immunoblotting. When
procollagen VII from cell extracts was used as a substrate, the
extracts were concentrated by precipitation with 176 mg/ml ammonium
sulfate, and the protein precipitate was harvested by centrifugation
for 1 h at 4 °C and 13,000 rpm. The protein pellet was
resuspended in 400 µl/75 cm2 of the above assay buffer
and dialyzed against the same buffer overnight. After dialysis,
protease inhibitors were added, and the sample was incubated in the
presence of BMP-1 as described above. Protein precipitation and
analysis were carried out as mentioned above.
N-terminal Sequencing--
After cleavage of the truncated
procollagen VII with BMP-1, mTLL-1, or mTLL-2, the cleavage products
were separated by SDS-PAGE and transferred to high capacity
protein-binding membrane (Sequi-Blot polyvinylidene difluoride
membrane, Bio-Rad). After staining with Coomassie Brilliant Blue, the
band corresponding to the C-propeptide was excised and subjected to
N-terminal microsequencing using Edman degradation (Toplab,
Martinsried, Germany, and Microsequencing Facility of the
Massachusetts General Hospital, Boston).
Analysis of BMP-1 Activity--
Media were obtained from primary
human keratinocytes and fibroblasts as described above. 94 µl of
medium were each incubated with 1 µg of
L-Pro-14C-human procollagen I for 8 h
at 37 °C in the presence of 50 mM Tris-HCl, pH 7.5, 5 mM CaCl2, 0.02% (w/v) dextran sulfate, 0.01% (w/v) Brij-35, and 0.02% (w/v) sodium azide (49). Incubation of
radioactively labeled procollagen I in the absence of cell culture
medium served as a negative control, and incubation in the presence of
recombinant human BMP-1 served as a positive control, respectively.
Samples were separated by 7.5% SDS-PAGE, followed by blotting and
exposure to film.
Immunohistochemistry--
Collagen VII was detected using the
polyclonal antibody NC1-F3 that recognizes the NC-1 domain of collagen
VII.3 The monoclonal antibody "2H1" directed against
mTLL-1 was a kind gift from Paul Findell and Suzanne Spong, FibroGen
Inc., South San Francisco, CA. The polyclonal antibodies "AB81032"
directed against the N terminus of BMP-1/mTLD and "AB81030" against
the C terminus of mTLD were purchased from Chemicon, Temecula, CA. The
fluorescein isothiocyanate-labeled anti-rabbit/anti-mouse antibodies
were from Dako (Glostrup, Denmark). Cells were cultured on coverslips
in the presence of 50 µg/ml L-ascorbic acid for 48 h, permeabilized, and fixed with absolute methanol at 20 °C. For
immunofluorescence staining, cells and tissue cryosections were
incubated at room temperature with the first antibody overnight and the
second antibody for 1 h. Preparations were mounted with Mowiol
(Hoechst, Frankfurt am Main, Germany) and examined using a fluorescence
microscope (Axioskop 2, equipped with either an MC 80 DX camera or an
AxioCam HRc digital camera, Carl Zeiss, Oberkochen, Germany) at a
wavelength of 488 nm. For immunoperoxidase staining, the specimens were
incubated with the primary antibody in phosphate-buffered saline
containing 1% (w/v) bovine serum albumin overnight at room temperature
followed by incubation with the peroxidase-conjugated secondary
antibody (EnVision, DAKO, Glostrup, Denmark) for 30 min at room
temperature. Peroxidase activity was visualized using chromogenic
3-amino-9-ethylcarbazole (Sigma) in 50 mM acetic
acid/sodium acetate, pH 4.7, in the presence of
H2O2 at 37 °C for 10 min. Cells were
counterstained with Mayer's hemalum solution (Merck) and washed with
water. The slides were mounted with Gurr Aquamount (BDH Laboratory
Supplies, Poole, UK) and analyzed by light microscopy.
 |
RESULTS |
Expression and Characterization of Recombinant Truncated
Procollagen VII--
Preliminary experiments with BMP-1 purified from
osteosarcoma cell lines indicated that BMP-1 was able to cleave
procollagen VII isolated from cultured human keratinocytes. However,
only minute amounts of the released C-propeptide were retrieved after the cleavage, impeding the determination of the cleavage site. Therefore, a recombinant truncated procollagen VII was produced for
characterization of the BMP-1 processing of procollagen VII and for
determination of the cleaved peptide bond. The cDNA construct encoded a fusion product of procollagen VII amino acids 1042-1284 to
amino acids 2684-2944, resulting in the deletion of the N-terminal portion of the NC-1 domain and of the central portion of the triple helical domain (Fig. 1, A and
B). However, the von Willebrand factor domain and the
cysteine-rich sequences within the NC-1 domain, the N- and C-terminal
parts of the triple helix, and the entire NC-2 domain were retained.
The construct was thus distinctly smaller than the type VII
minicollagen produced by Chen et al. (50) that contained the
full-length NC-1 domain. Truncated procollagen VII was secreted into
the conditioned medium of mass cultures of confluent 293-EBNA cells at
a concentration of ~0.5 mg/liter and was purified by affinity
chromatography on nickel-Sepharose. Immunoblotting with domain-specific
collagen VII antibodies showed that the recombinant truncated
procollagen VII contained the NC-1, triple-helical, and NC-2 domains
(Fig. 1C). SDS-PAGE under non-reducing and reducing
conditions indicated that the protein was trimeric containing
intermolecular disulfide bonds (Fig.
2A). The trimer migrated as a
double band leading to the assumption that it consisted of two forms
with different intermolecular disulfide bonds and conformations. Both
reduced and unreduced monomers migrated as a single band indicating
that the double band of the trimer was not due to proteolytic
degradation. The unreduced monomer had a smaller apparent molecular
weight than the reduced monomer, suggesting also intramolecular
disulfide bonding. Incubation with highly purified bacterial
collagenase digested the triple helix, yielding the N- and C-terminal
globular domains (Fig. 2B), whereas treatment with pepsin
removed these domains thus leaving the central helical domain (Fig.
2C). The primary structure predicts one glycosylation site
within the truncated NC-1 domain. Incubation of the protein with
N-glycosidase F leads to a slight reduction of the molecular weight indicating that the protein is glycosylated (Fig.
2D). These experiments showed that the recombinant protein
had the predicted structure and was suitable for use as a substrate for BMP-1.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 1.
Construction of recombinant truncated
procollagen VII. A, schematic representation of
full-length human procollagen VII. A pro- 1(VII) chain contains 2944 amino acids. NC-1 and NC-2, globular N- and
C-terminal domains (gray boxes); P2 and
P1, triple-helical domains; HG, central globular
hinge region; N, putative N-linked glycosylation
sites. The amino acid sequence encoded by exon 115 is indicated. The
arrow marks the BMP-1 cleavage site within exon 115. The
black bars indicate the recognition sites of the antibodies
used in this study. B, schematic representation of the
fusion construct for the truncated procollagen VII. The black
arrow symbolizes the two parts of the full-length protein that
were combined; amino acids 1042-1284 were fused to amino acids
2684-2944. The construct contains an octa-His tag at its C terminus.
The scissors indicates the location of the BMP-1 cleavage
site. The new N-terminal sequence after cleavage is shown.
C, in immunoblots, antibodies NC1-F3,
VII-aff, and NC2-10 domains recognized the
recombinant procollagen VII and confirmed that it had the predicted
structure.
|
|

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 2.
Structural characterization of recombinant
truncated procollagen VII. A, the truncated procollagen
VII was separated on a 7.5% SDS-PAGE under non-reducing ( ) or
reducing conditions (+) and subjected to immunoblotting with the
antibody NC2-10. T, trimer; M, monomer.
-ME, -mercaptoethanol. B, collagenase
digested the central triple-helical domain of the truncated procollagen
VII and released the NC-1 and NC-2 domains. The immunoblots (15%
SDS-PAGE) were decorated either with antibody NC1-F3 or NC2-10 to
visualize NC-1 and NC-2 domain, respectively. , no enzyme treatment;
+, collagenase treatment. C, pepsin degraded the globular
NC-1 and NC-2 domains of truncated procollagen VII. The immunoblot
(15% SDS-PAGE) was decorated with the antibody NC2-10, which
recognizes the triple-helical and NC-2 domains. , no enzyme
treatment; +, pepsin digestion; Co, undigested control;
H, triple-helical domain. D,
N-glycosidase F (N-glyc. F) treatment of the
truncated procollagen VII removed N-linked carbohydrates
from the molecule, resulting in faster migration on a 7.5% SDS-PAGE.
Immunoblot with the antibody NC2-10. , no enzyme treatment; +,
N-glycosidase F treatment; Co, a sample kept at
20 °C.
|
|
BMP-1, mTLL-1, and mTLL-2 Process Procollagen VII in
Vitro--
The truncated procollagen VII was efficiently cleaved by
recombinant BMP-1 (Fig. 3A).
The C-propeptide was subjected to N-terminal microsequencing, which
yielded a major DTAGS sequence. This showed that BMP-1 cleaved the
peptide bond between Ala2821 and Asp2822,
corresponding to the predicted BMP-1 consensus cleavage site SYAA DTAG. A second minor sequence obtained was
-LHAVP. This sequence is located within the NC-2 domain, six
amino acid residues away from the C terminus of the P1'
consensus cleavage site and is likely to represent secondary
degradation. The truncated procollagen VII was also subjected to
digestion by recombinant human mTLL-1 and mTLL-2, two metalloproteases
related to BMP-1 that share at least some substrates with BMP-1. Both
enzymes cleaved the truncated procollagen VII, and microsequencing
demonstrated that the cleavage occurred at the same
Ala2821-Asp2822 bond as with BMP-1. However,
cleavage by mTLL-2 seemed to be less efficient because under the same
conditions only about half of the substrate was converted. The
digestion of truncated procollagen VII by BMP-1 was inhibited by metal
chelators, such as 10 mM EDTA and 1 mM
o-phenanthroline, or by 5 mM 2,2'-bipyridine, 1 mM 1,4-dithio-DL-threitol, and 1 mM
Zn2+ but not by serine or cysteine proteinase inhibitors,
such as 10 µg/ml leupeptin, 1 mM phenylmethylsulfonyl
fluoride, 1 mM AEBSF, 2 mM
N-ethylmaleimide, or 10 µg/ml soybean trypsin inhibitor. Heat denaturation of the procollagen did not inhibit cleavage (not
shown).

View larger version (106K):
[in this window]
[in a new window]
|
Fig. 3.
Cleavage of recombinant truncated procollagen
VII with BMP-1-like enzymes. A, immunoblots after
enzyme reactions (12.5% SDS-PAGE). The blots were developed using the
antibodies NC1-F3 and NC2-7 to show both N- and C-terminal fragments,
respectively. 1st panel, cleavage with recombinant BMP-1.
2nd panel, processing with recombinant mTLL-1. 3rd
panel, cleavage with recombinant mTLL-2. 4th panel,
processing with recombinant BMP-1, detection of the C-propeptide. ,
sample incubated without enzyme; +, sample incubated with enzyme;
pro., truncated procollagen VII; mat., mature
truncated procollagen VII from which the C-propeptide has been removed;
C-pep., C-propeptide. B, rotary shadowing images
of miniprocollagen VII before (a-e) and after
(f-k) BMP-1 digestion. The recombinant truncated
procollagen VII molecule has N- and C-terminal globular domains of
approximately the same size. Digestion with BMP-1 removed one globule.
Bar, 50 nm.
|
|
Rotary shadowing of the recombinant truncated procollagen VII
demonstrated the presence of rod-like molecules with small globules at
both ends. The measured length of the rod, 35 nm, corresponded to the
predicted size of 36 nm calculated from the length of the triple-helical domain of the authentic full-length type VII collagen (27). Digestion of the procollagen with BMP-1 resulted in the removal
of one of the globules (Fig. 3B).
To verify the cleavage observed with the recombinant protein,
full-length authentic procollagen VII was partially purified from human
keratinocyte cultures and used as a substrate for recombinant BMP-1.
The reaction resulted in the conversion of the 320-kDa pro- 1(VII)
chains to 290-kDa 1(VII) chains, which co-migrated with mature
1(VII) chains from normal human dermis. The processing was inhibited
in the presence of 25 mM EDTA (Fig.
4).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
Authentic full-length human procollagen VII
is processed by BMP-1. Human procollagen VII isolated from normal
keratinocytes was digested with BMP-1 and immunoblotted (5% SDS-PAGE)
with antibody NC2-10. Lane 1, negative control kept at
20 °C. Lane 2, sample incubated with BMP-1. Lane
3, sample incubated with BMP-1 in the presence of 25 mM EDTA. Lane 4, negative control incubated
without BMP-1. Lane 5, mature collagen VII isolated from
normal human skin. pro, 320-kDa human procollagen VII;
mat., 290-kDa mature human collagen VII.
|
|
Procollagen with a Deletion of the BMP-1 Consensus Sequence Is Not
Processed--
Mutated procollagen VII was isolated from keratinocytes
of two DEB patients. Both carried the deletion mutation 8523del14 on
one allele of the COL7A1 gene (32). The mutation leads to in-frame skipping of exon 115 that encodes a segment of 29 amino acids
containing the putative BMP-1 consensus sequence. In addition, the
deletion mutation results in the amino acid substitution E2843Q. On the
other allele, patient 1 carried the nonsense mutation A425G and
was thus functionally homozygous for the deletion, i.e.
synthesized only homotrimers consisting of deleted pro- 1(VII)
chains. Patient 2 had a glycine substitution mutation G2009R on the
other allele and was thus compound heterozygous for two different
mutations. The prediction was that the keratinocytes of patient 2 synthesized mixed trimers containing deleted pro- 1(VII) chains and
1(VII) chains with a glycine substitution in the central
triple-helical domain. Collagen VII was extracted from skin samples of
both patients and analyzed by immunoblotting. Only procollagen VII was
found in the skin of patient 1, supporting the prediction that the
deletion inhibited processing by BMP-1 (Fig.
5A). In the skin of patient 2, procollagen VII was partially processed (Fig. 5A),
indicating that pro- 1(VII) chains with the glycine
substitution were cleaved but not the pro- 1(VII) chains containing
the deletion. The inability of BMP-1 to cleave the mutated procollagen
VII of patient 1 was confirmed in vitro. Procollagen VII was
extracted from keratinocytes of patient 1 and digested with BMP-1. In
contrast to normal procollagen VII, no cleavage of the mutated
molecules was observed (Fig. 5B).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 5.
Mutant procollagen VII with deletion of the
BMP-1 consensus sequence is not processed. A,
immunoblot of skin extracts from two patients with a deletion of the
BMP-1 cleavage site. Patient 1 is functionally homozygous for the
deletion and has only deleted pro- 1(VII) chains. Patient 2 is
compound heterozygous for the deletion and a missense mutation and has
a mixture of deleted pro- 1(VII) chains and pro- 1(VII) chains with
a glycine substitution within the triple helix. Lanes 1 and
6, procollagen VII (pro) from normal human
keratinocytes. Lanes 2 and 5, mature
(mat.) collagen VII from normal human skin. Lane
3, collagen VII from the skin of patient 1, only a procollagen
band is seen. Lane 4, collagen VII from the skin of patient
2, both procollagen and mature collagen are found. The immunoblot on
5% SDS-PAGE was detected with antibody NC2-10. B,
procollagen VII isolated from cultured keratinocytes of patient 1 is
not processed by recombinant BMP-1 in vitro. Lane
1, sample incubated without enzyme. Lane 2, sample
incubated with BMP-1. Lane 3, mature collagen VII from
normal human skin. Lane 4, procollagen VII from normal human
keratinocytes.
|
|
Cutaneous Cells Express Enzymes of the BMP-1
Family--
Immunohistochemical staining with a polyclonal antibody
recognizing BMP-1 and its alternatively spliced form mTLD showed a positive signal in cultured keratinocytes and fibroblasts (Fig. 6). In the skin, both mesenchymal and
epidermal cells produced a positive signal, with the most prominent
staining in basal keratinocytes. The same result was obtained using an
antibody specific for mTLD (data not shown). Immunofluorescence
staining with a monoclonal antibody directed against mTLL-1 also gave a
positive signal in cultured keratinocytes and fibroblasts. However, in
the skin, mTLL-1 was detected only in the suprabasal epidermis. This
suggests that in vivo, BMP-1/mTLD but not mTLL-1 is the
major protease involved in procollagen processing in normal skin. To
differentiate between latent pro-forms and mature, biologically active
enzymes, culture media of human keratinocytes and fibroblasts were
tested for procollagen C-proteinase activity using
14C-labeled procollagen I as a substrate. It was partially
cleaved to pNcollagen and mature collagen I during incubation with
fibroblast medium, but no processing was detected with keratinocyte
medium (Fig. 7). This suggests that both
keratinocytes and fibroblasts produce BMP-1/mTLD but that keratinocytes
secrete mainly the latent pro-forms, whereas mesenchymal cells produce
most of the enzymatically active enzymes. This is consistent
with previous observations (51) using immunoblot analysis that cultured
fibrogenic cells secrete mostly mature, active BMP-1/mTLD, whereas
keratinocytes produce predominantly the unprocessed precursor.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 6.
Immunohistochemical analysis of
BMP-1/mTLD and mTLL-1 expression in normal human keratinocytes and
fibroblasts. Staining of BMP-1/mTLD in keratinocytes
(a) and fibroblasts (b) is shown. The
corresponding negative controls are shown in c and
d. Immunodetection of mTLL-1 in keratinocytes
(e), fibroblasts (f), and in the epidermis of
normal human skin (g) is shown. The corresponding negative
controls are shown in h-k.
|
|

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 7.
Activity of BMP-1-like enzymes in culture
medium of skin fibroblasts and keratinocytes. Autoradiogram of
14C-labeled human procollagen I incubated with culture
medium. 1st lane, procollagen I standard (Std.).
2nd lane, procollagen I incubated with keratinocyte medium
(K). 3rd lane, procollagen I incubated with
fibroblast medium (F). 4th lane, procollagen I
incubated with recombinant BMP-1 (+). 5th lane, negative
control, incubation without enzyme ( ). 7.5% SDS-PAGE.
|
|
Procollagen VII Is Processed in BMP-1-deficient Mice--
Because
procollagen VII can be processed by three enzymes, BMP-1, mTLL-1, and
mTLL-2, in vitro, we investigated the processing in the skin
of Bmp1 / mouse embryos (18 dpc). Previous data (41) had
shown that homozygous Bmp1 null mice were perinatally lethal, with defects in procollagen I processing and collagen fibrillogenesis, but with residual procollagen C-proteinase activity. In concert with those observations, immunofluorescence staining with
collagen VII antibodies produced a strong reaction along the
dermal-epidermal junction in both wild type and Bmp1 /
mouse embryo skin (Fig. 8A),
indicating that collagen VII content was not reduced in Bmp1
/ mouse skin. Immunoblotting of dermis extracts of Bmp1
/ mice showed that procollagen VII was processed similarly to wild
type mice (Fig. 8B). These data suggest that mTLL-1 and/or mTLL-2 can fully substitute for BMP-1/mTLD in procollagen VII processing in vivo.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 8.
Collagen VII is fully processed in the skin
of Bmp-1 /
mice. A, immunofluorescence staining of collagen
VII in the skin of Bmp1 / (upper left panel)
and wild type mice (lower left panel). Note that the
staining pattern is similar in both mice. Right panels show
corresponding negative controls. B, immunoblot of collagen
VII in mouse skin extracts. Lane 1, normal human skin.
Lane 2, wild type mouse skin. Lane 3,
Bmp1 / mouse skin. Lane 4, procollagen VII
from extracts of normal human keratinocytes. The blot was on 5%
SDS-PAGE and developed with antibody NC2-10. mat, mature;
pro, procollagen.
|
|
 |
DISCUSSION |
Here we show that BMP-1-like proteinases cleave procollagen VII to
mature anchoring fibril collagen in the skin. Cleavage of procollagen
VII by BMP-1 is similar to the cleavage of procollagens I-III because
a C-propeptide is efficiently removed from the procollagen molecule.
Noteworthy, the cleavage of the C-propeptide of procollagen V requires
furin (5-7). Other BMP-1 substrates, such as probiglycan (8), prolysyl
oxidase (21, 22), chordin (18), and the 3 and 2 chains of laminin
5 (9, 10, 36) have different molecular structures and functions. Thus,
BMP-1-like proteinases control a variety of biological functions,
ranging from polymerization of different tissue-specific collagen
fibrils (23, 24), proteoglycan maturation, or cross-linking of
collagens and elastin to dorsal-ventral patterning during embryogenesis
and to dermal-epidermal cohesion (26).
The importance of the above biological functions is alluded to by the
redundancy of the enzymes. For example, as shown here, three members of
the astacin family, BMP-1, mTLL-1, and mTLL-2 have the ability to
cleave procollagen VII at the same specific site in vitro.
Genetic, immunohistological, and activity assays demonstrated that at
least BMP-1 and mTLL-1 are produced and active in the skin, whereas the
lack of mTLL-2-specific antibodies leaves open the question of whether
this enzyme might also be expressed at detectable levels in normal
skin. To address the issue of whether proteases other than BMP-1 or
mTLL-1 are able to cleave procollagen VII, we attempted analysis of
procollagen VII processing in the skin of embryos lacking both enzymes.
Such embryos are doubly homozygous null for the Bmp1 gene,
which encodes both BMP-1 and mTLD, and for the Tll1 gene,
which encodes mTLL-1, and were produced by intercrossing heterozygotes
from Bmp1 described previously (41) and Tll1
knockout mouse lines (52). However, the doubly null embryos die during
embryonic development at 14-15 dpc, at which stage the skin basement
membrane zone is undeveloped, extremely fragile, and not amenable to
immunohistological or protein chemical analysis. Thus, although it
appears that under physiological conditions BMP-1 and mTLL-1 both
appear capable of processing procollagen VII in the skin, it remains to
be determined whether these two enzymes are capable of substituting for
each other, and whether mTLL-2 may substitute for either or both of the
other two related enzymes in vivo. Future experiments should
be directed toward resolving such issues as well as assessing possible
other functions of these proteinases apart from processing of
extracellular matrix proteins.
Early biochemical characterization of procollagen VII demonstrated
efficient cleavage of the C-propeptide and predicted that the removal
is important for polymerization of the anchoring fibrils (53, 54).
Genetic evidence supports this notion. In a subset of recessive DEB, a
human blistering skin disease, the BMP-1 consensus motif is deleted,
and procollagen VII accumulates in the skin. As illustrated by patient
1, who is functionally homozygous (hemizygous) for the deletion of a
29-amino acid segment containing the BMP-1 cleavage site, the mutated
anchoring fibrils are ultrastructurally abnormal and functionally
deficient, clearly demonstrating the significance of adequate
procollagen-to-collagen VII processing for adhesion of the epidermis
and the dermis.
The dermal-epidermal junction is a large epithelial-mesenchymal
interface that regulates a number of skin functions. It consists of
structurally complex multiprotein aggregates designed to provide firm
adhesion on the one hand between the basal epidermal keratinocytes and
the basement membrane and on the other hand between the basement membrane and the papillary dermis. Besides interacting with each other
as binding ligands to provide adhesion, the protein components of the
junction also mediate cell adhesion, migration, and signal transduction
of messages from the extracellular matrix to the keratinocytes. The
regulation of these processes occurs at several levels.
Post-translational proteolytic cleavage of several of the proteins
modifies their functions and is, therefore, an important regulatory
mechanism. For example, the shedding of the transmembrane collagen XVII
from keratinocyte surfaces (48) or cleavage of laminin 5 arms
influences cell adhesion and migration (10, 38). Additionally, as shown
in the present study, extracellular processing of procollagen VII to
collagen is a prerequisite for correct polymerization of the anchoring
fibrils. Other proteolytically processed components of the
dermal-epidermal junction include 6 integrin (55)
and dystroglycan (56). However, the functional consequences of their cleavage remain elusive.
The laminin 5 precursor and procollagen VII are synthesized and
secreted by epidermal keratinocytes. In contrast, active BMP-1-like enzymes seem to originate mainly from mesenchymal fibroblasts (57, 58).
Accordingly, we could not demonstrate BMP-1-like activity in
keratinocyte culture medium, whereas we confirmed the finding that
BMP-1/mTLD and maybe other proteases with similar activity are active
in culture media of skin fibroblasts. In agreement with the observation
of Amano et al. (9) that antibodies to BMP-1 stained basal
epidermal keratinocytes in calf skin, we found a positive signal for
BMP-1/mTLD in cultured human keratinocytes in vitro.
However, in light of the activity assays, it seems feasible that
keratinocytes secrete BMP-1/mTLD predominantly in the latent zymogen
forms. This assumption is in agreement with the previous data that show
that transforming growth factor- 1-stimulated keratinocytes produce mainly pro-forms of BMP-1 and mTLD in the presence of a low
calcium concentration (0.15 mM Ca2+) (51).
Pro-BMP-1/mTLD possesses a consensus sequence for processing by
furin-type proprotein convertases. Furin itself is known to need a low
pH and Ca2+ for activation (59). The primary keratinocytes
used in our experiments were maintained also at a low calcium
concentration (<0.1 mM Ca2+) to keep the cells
at a low state of differentiation similar to the situation found for
the basal keratinocytes in the skin. In the presence of higher calcium
concentrations (1.5 mM), the keratinocytes start to
differentiate, i.e. they form several cell layers and start
to cornify. That BMP-1 seems to be activated in the presence of higher
calcium concentrations is in agreement with the previous observation
that the 2 chain of laminin 5 is processed in keratinocyte culture
supernatants only in the presence of at least 1 mM
Ca2+ (9). The epithelial substrate-mesenchymal enzyme
constellation presents novel ways of regulating epithelial-mesenchymal
interactions, such as the assembly of the dermal epidermal junction,
cell adhesion, and migration during development and reparative processes.
 |
ACKNOWLEDGEMENTS |
We thank Margit Schubert for excellent
technical assistance. Paul Findell and Suzanne Spong, FibroGen Inc.,
South San Francisco, CA, kindly provided the mTLL-1 antibody.
 |
FOOTNOTES |
*
This work was supported in part by the German Research
Council, DFG, Grant SFB 492-A3, the Interdisciplinary Center for
Clinical Research, University of Münster, Grant IZKF D-17 (to
L. B.-T.), and by National Institutes of Health Grants AR47746 and
GM63471 (to D. S. G.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§§
To whom correspondence should be addressed: Dept. of
Dermatology, University of Münster, Von-Esmarch-Str.
58, D-48149 Münster, Germany. Tel.: 49-251-835-6534;
Fax: 49-251-835-2559; E-mail: tuderma@uni-muenster.de.
Published, JBC Papers in Press, May 1, 2002, DOI 10.1074/jbc.M203247200
1
C.-W. Franzke, K. Tasanen, H. Schäcke, Z. Zhou, K. Tryggvason, C. Mauch, P. Zigrino, S. Sunnarborg, D. C. Lee, F. Fahrenholz, and L. Bruckner-Tuderman, submitted for publication.
3
S. Mecklenbeck, H. S. Compton,
J. E. Mejía, R. Cervini, A. Hovnanian, and L. Bruckner-Tuderman, submitted for publication.
 |
ABBREVIATIONS |
The abbreviations used are:
BMP-1, bone
morphogenetic protein-1;
AEBSF, 4-(2-aminoethyl)benzenesulfonyl
fluoride;
C-propeptide, C-terminal propeptide;
DEB, dystrophic
epidermolysis bullosa;
dpc, dies post-conception;
mTLD, mammalian tolloid;
mTLL, mammalian tolloid-like.
 |
REFERENCES |
| 1.
|
Eder, J.,
and Fersht, A. R.
(1995)
Mol. Microbiol.
16,
609-614[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Kessler, E.,
Takahara, K.,
Biniaminov, L.,
Brusel, M.,
and Greenspan, D. S.
(1996)
Science
271,
360-362[Abstract]
|
| 3.
|
Li, S. W.,
Sieron, A. L.,
Fertala, A.,
Hojima, Y.,
Arnold, W. V.,
and Prockop, D. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5127-5130[Abstract/Free Full Text]
|
| 4.
|
Prockop, D. J.,
Sieron, A. L.,
and Li, S. W.
(1998)
Matrix Biol.
16,
399-408[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Imamura, Y.,
Steiglitz, B. M.,
and Greenspan, D. S.
(1998)
J. Biol. Chem.
273,
27511-27517[Abstract/Free Full Text]
|
| 6.
|
Kessler, E.,
Fichard, A.,
Chanut-Delalande, H.,
Brusel, M.,
and Ruggiero, F.
(2001)
J. Biol. Chem.
276,
27051-27057[Abstract/Free Full Text]
|
| 7.
|
Unsöld, C.,
Pappano, W. N.,
Imamura, Y.,
Steiglitz, B. M.,
and Greenspan, D. S.
(2002)
J. Biol. Chem.
277,
5596-5602[Abstract/Free Full Text]
|
| 8.
|
Scott, I. C.,
Imamura, Y.,
Pappano, W. N.,
Troedel, J. M.,
Recklies, A. D.,
Roughley, P. J.,
and Greenspan, D. S.
(2000)
J. Biol. Chem.
275,
30504-30511[Abstract/Free Full Text]
|
| 9.
|
Amano, S.,
Scott, I. C.,
Takahara, K.,
Koch, M.,
Champliaud, M. F.,
Gerecke, D. R.,
Keene, D. R.,
Hudson, D. L.,
Nishiyama, T.,
Lee, S.,
Greenspan, D. S.,
and Burgeson, R. E.
(2000)
J. Biol. Chem.
275,
22728-22735[Abstract/Free Full Text]
|
| 10.
|
Gagnoux-Palacios, L.,
Allegra, M.,
Spirito, F.,
Pommeret, O.,
Romero, C.,
Ortonne, J. P.,
and Meneguzzi, G.
(2001)
J. Cell Biol.
153,
835-850[Abstract/Free Full Text]
|
| 11.
|
Fitzgerald, M. L.,
Wang, Z.,
Park, P. W.,
Murphy, G.,
and Bernfield, M.
(2000)
J. Cell Biol.
148,
811-824[Abstract/Free Full Text]
|
| 12.
|
Felbor, U.,
Dreier, L.,
Bryant, R. A.,
Ploegh, H. L.,
Olsen, B. R.,
and Mothes, W.
(2000)
EMBO J.
19,
1187-1194[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
McCawley, L. J.,
and Matrisian, L. M.
(2001)
Curr. Opin. Cell Biol.
13,
534-540[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Bode, W.,
Gomis-Rüth, F. X.,
and Stöcker, W.
(1993)
FEBS Lett.
331,
134-140[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Bond, J. S.,
and Beynon, R. J
(1995)
Protein Sci.
4,
1247-1261[Medline]
[Order article via Infotrieve]
|
| 16.
|
Takahara, K.,
Lyons, G. E.,
and Greenspan, D. S.
(1994)
J. Biol. Chem.
269,
32572-32578[Abstract/Free Full Text]
|
| 17.
|
Takahara, K.,
Brevard, R.,
Hoffman, G. G.,
Suzuki, N.,
and Greenspan, D. S.
(1996)
Genomics
34,
157-165[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Scott, I. C.,
Blitz, I. L.,
Pappano, W. N.,
Imamura, Y.,
Clark, T. G.,
Steiglitz, B. M.,
Thomas, C. L.,
Maas, S. A.,
Takahara, K.,
Cho, K. W. Y.,
and Greenspan, D. S.
(1999)
Dev. Biol.
213,
283-300[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Hojima, Y.,
van der Rest, M.,
and Prockop, D. J.
(1985)
J. Biol. Chem.
260,
15996-16003[Abstract/Free Full Text]
|
| 20.
|
Kessler, E.,
Adar, R.,
Goldberg, B.,
and Niece, R.
(1986)
Collagen Relat. Res.
6,
249-266
|
| 21.
|
Panchenko, M. V.,
Stetler-Stevenson, W. G.,
Trubetskoy, O. V.,
Gacheru, S. N.,
and Kagan, H. M.
(1996)
J. Biol. Chem.
271,
7113-7119[Abstract/Free Full Text]
|
| 22.
|
Uzel, M. I.,
Scott, I. C.,
Babakhanlou-Chase, H.,
Palamakumbura, A. H.,
Pappano, W. N.,
Hong, H.-H.,
Greenspan, D. S.,
and Trackman, P. C.
(2001)
J. Biol. Chem.
276,
22537-22543[Abstract/Free Full Text]
|
| 23.
|
Kadler, K. E.,
Hojima, Y.,
and Prockop, D. J.
(1987)
J. Biol. Chem.
262,
15696-15701[Abstract/Free Full Text]
|
| 24.
|
Hulmes, D. J. S.,
Kadler, K. E.,
Mould, A. P,
Hojima, Y.,
Holmes, D. F.,
Cummings, C.,
Chapman, J. A.,
and Prockop, D. J.
(1989)
J. Mol. Biol.
210,
337-345[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Scott, I. C.,
Blitz, I. L.,
Pappano, W. N.,
Maas, S. A.,
Cho, K. W.,
and Greenspan, D. S.
(2001)
Nature
410,
475-478[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Burgeson, R. E.,
and Christiano, A. M.
(1997)
Curr. Opin. Cell Biol.
9,
651-658[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Morris, N. P.,
Keene, D. R.,
Glanville, R. W.,
Bentz, H.,
and Burgeson, R. E.
(1986)
J. Biol. Chem.
261,
5638-5644[Abstract/Free Full Text]
|
| 28.
|
Lunstrum, G. P.,
Sakai, L. Y.,
Keene, D. R.,
Morris, N. P.,
and Burgeson, R. E.
(1986)
J. Biol. Chem.
261,
9042-9048[Abstract/Free Full Text]
|
| 29.
|
Keene, D. R.,
Sakai, L. Y.,
Lunstrum, G. P.,
Morris, N. P.,
and Burgeson, R. E.
(1987)
J. Cell Biol.
104,
611-621[Abstract/Free Full Text]
|
| 30.
|
Bruckner-Tuderman, L.
(1999)
J. Dermatol. Sci.
20,
122-133[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Bruckner-Tuderman, L.,
Höpfner, B.,
and Hammami-Hauasli, N.
(1999)
Matrix Biol.
18,
43-54[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Bruckner-Tuderman, L.,
Nilssen, O.,
Zimmermann, D. R.,
Dours-Zimmermann, M. T.,
Kalinke, D. U.,
Gedde-Dahl, T., Jr.,
and Winberg, J. O.
(1995)
J. Cell Biol.
131,
551-559[Abstract/Free Full Text]
|
| 33.
|
Chen, M.,
Keene, D. R.,
Costa, F. K.,
Tahk, S. H.,
and Woodley, D. T.
(2001)
J. Biol. Chem.
276,
21649-21655[Abstract/Free Full Text]
|
| 34.
|
Christiano, A. M.,
Greenspan, D. S.,
Lee, S.,
and Uitto, J.
(1994)
J. Biol. Chem.
269,
20256-20262[Abstract/Free Full Text]
|
| 35.
|
Rousselle, P.,
Keene, D. R.,
Ruggiero, F.,
Champliaud, M. F.,
Rest, M.,
and Burgeson, R. E.
(1997)
J. Cell Biol.
138,
719-728[Abstract/Free Full Text]
|
| 36.
|
Sasaki, T.,
Göhring, W.,
Mann, K.,
Brakebusch, C.,
Yamada, Y.,
Fässler, R.,
and Timpl, R.
(2001)
J. Mol. Biol.
314,
751-763[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Koshikawa, N.,
Giannelli, G.,
Cirulli, V.,
Miyazaki, K.,
and Quaranta, V.
(2000)
J. Cell Biol.
148,
615-624[Abstract/Free Full Text]
|
| 38.
|
Tunggal, L.,
Ravaux, J.,
Pesch, M.,
Smola, H.,
Krieg, T.,
Gaill, F.,
Sasaki, T.,
Timpl, R.,
Mauch, C.,
and Aumailley, M.
(2002)
Am. J. Pathol.
160,
459-468[Abstract/Free Full Text]
|
| 39.
|
König, A.,
and Bruckner-Tuderman, L.
(1994)
Lab. Invest.
70,
203-209[Medline]
[Order article via Infotrieve]
|
| 40.
|
Hammami-Hauasli, N.,
Schumann, H.,
Raghunath, M.,
Kilgus, O.,
Lüthi, U.,
Luger, T.,
and Bruckner-Tuderman, L.
(1998)
J. Biol. Chem.
273,
19228-19234[Abstract/Free Full Text]
|
| 41.
|
Suzuki, N.,
Labosky, P. A.,
Furuta, Y.,
Hargett, L.,
Dunn, R.,
Fogo, A. B.,
Takahara, K.,
Peters, D. M.,
Greenspan, D. S.,
and Hogan, B. L.
(1996)
Development
122,
3587-3595[Abstract]
|
| 42.
|
König, A.,
and Bruckner-Tuderman, L.
(1992)
J. Cell Biol.
117,
679-685[Abstract/Free Full Text]
|
| 43.
|
Betts, C. M.,
Posteraro, P.,
Costa, A. M.,
Varotti, C.,
Schubert, M.,
Bruckner-Tuderman, L.,
and Castiglia, D.
(1999)
Br. J. Dermatol.
141,
833-839[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Gardella, R.,
Belletti, L.,
Zoppi, N.,
Marini, D.,
Barlati, S.,
and Colombi, M.
(1996)
Am. J. Hum. Genet.
59,
292-300[Medline]
[Order article via Infotrieve]
|
| 45.
|
Arnold, U.,
and Ulbrich-Hofmann, R.
(1999)
Anal. Biochem.
271,
197-199[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Bruckner-Tuderman, L.,
Schnyder, U. W.,
Winterhalter, K. H.,
and Bruckner, P.
(1987)
Eur. J. Biochem.
165,
607-611[Medline]
[Order article via Infotrieve]
|
| 47.
|
Kohfeldt, E.,
Maurer, P.,
Vannahme, C.,
and Timpl, R.
(1997)
FEBS Lett.
414,
557-561[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Schäcke, H.,
Schumann, H.,
Hammami-Hauasli, N.,
Raghunath, M.,
and Bruckner-Tuderman, L.
(1998)
J. Biol. Chem.
273,
25937-25943[Abstract/Free Full Text]
|
| 49.
|
Hojima, Y.,
Behta, B.,
Romanic, A. M.,
and Prockop, D. J.
(1994)
Anal. Biochem.
223,
173-180[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Chen, M.,
O'Toole, E. A.,
Muellenhoff, M.,
Medina, E.,
Kasahara, N.,
and Woodley, D. T.
(2000)
J. Biol. Chem.
275,
24429-24435[Abstract/Free Full Text]
|
| 51.
|
Lee, S.,
Solow-Cordero, D. E.,
Kessler, E.,
Takahara, K.,
and Greenspan, D. S.
(1997)
J. Biol. Chem.
272,
19059-19066[Abstract/Free Full Text]
|
| 52.
|
Clark, T. G.,
Conway, S. J.,
Scott, I. C.,
Labosky, P. A.,
Winnier, G.,
Bundy, J.,
Hogan, B. L.,
and Greenspan, D. S.
(1999)
Development
126,
2631-2642[Abstract]
|
| 53.
|
Lunstrum, G. P.,
Kuo, H. J.,
Rosenbaum, L. M.,
Keene, D. R.,
Glanville, R. W.,
Sakai, L. Y.,
and Burgeson, R. E.
(1987)
J. Biol. Chem.
262,
13706-13712[Abstract/Free Full Text]
|
| 54.
|
Burgeson, R. E.
(1993)
J. Invest. Dermatol.
101,
252-255[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Delwel, G. O.,
Hogervorst, F.,
and Sonnenberg, A.
(1996)
J. Biol. Chem.
271,
7293-7296[Abstract/Free Full Text]
|
| 56.
|
Yamada, H.,
Saito, F.,
Fukuta-Ohi, H.,
Zhong, D.,
Hase, A.,
Arai, K.,
Okuyama, A.,
Maekawa, R.,
Shimizu, T.,
and Matsumura, K.
(2001)
Hum. Mol. Genet.
10,
1563-1569[Abstract/Free Full Text]
|
| 57.
|
Fukagawa, M.,
Suzuki, N.,
Hogan, B. L.,
and Jones, C. M.
(1994)
Dev. Biol.
163,
175-183[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Anderson, E. D.,
VanSlyke, J. K.,
Thulin, C. D.,
Jean, F.,
and Thomas, G.
(1997)
EMBO J.
16,
1508-1518[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Berry, T. A. Jowitt, J. Ferrand, M. Roessle, J. G. Grossmann, E. G. Canty-Laird, R. A. Kammerer, K. E. Kadler, and C. Baldock
Role of dimerization and substrate exclusion in the regulation of bone morphogenetic protein-1 and mammalian tolloid
PNAS,
May 26, 2009;
106(21):
8561 - 8566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Villone, A. Fritsch, M. Koch, L. Bruckner-Tuderman, U. Hansen, and P. Bruckner
Supramolecular Interactions in the Dermo-epidermal Junction Zone: ANCHORING FIBRIL-COLLAGEN VII TIGHTLY BINDS TO BANDED COLLAGEN FIBRILS
J. Biol. Chem.,
September 5, 2008;
283(36):
24506 - 24513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Maertens, D. Hopkins, C.-W. Franzke, D. R. Keene, L. Bruckner-Tuderman, D. S. Greenspan, and M. Koch
Cleavage and Oligomerization of Gliomedin, a Transmembrane Collagen Required for Node of Ranvier Formation
J. Biol. Chem.,
April 6, 2007;
282(14):
10647 - 10659.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, G. Ge, and D. S. Greenspan
Inhibition of Bone Morphogenetic Protein 1 by Native and Altered Forms of {alpha}2-Macroglobulin
J. Biol. Chem.,
December 22, 2006;
281(51):
39096 - 39104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Veit, B. Kobbe, D. R. Keene, M. Paulsson, M. Koch, and R. Wagener
Collagen XXVIII, a Novel von Willebrand Factor A Domain-containing Protein with Many Imperfections in the Collagenous Domain
J. Biol. Chem.,
February 10, 2006;
281(6):
3494 - 3504.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Selman, A. Pardo, L. Barrera, A. Estrada, S. R. Watson, K. Wilson, N. Aziz, N. Kaminski, and A. Zlotnik
Gene Expression Profiles Distinguish Idiopathic Pulmonary Fibrosis from Hypersensitivity Pneumonitis
Am. J. Respir. Crit. Care Med.,
January 15, 2006;
173(2):
188 - 198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Moali, B. Font, F. Ruggiero, D. Eichenberger, P. Rousselle, V. Francois, A. Oldberg, L. Bruckner-Tuderman, and D. J. S. Hulmes
Substrate-specific Modulation of a Multisubstrate Proteinase: C-TERMINAL PROCESSING OF FIBRILLAR PROCOLLAGENS IS THE ONLY BMP-1-DEPENDENT ACTIVITY TO BE ENHANCED BY PCPE-1
J. Biol. Chem.,
June 24, 2005;
280(25):
24188 - 24194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Petropoulou, L. Garrigue-Antar, and K. E. Kadler
Identification of the Minimal Domain Structure of Bone Morphogenetic Protein-1 (BMP-1) for Chordinase Activity: CHORDINASE ACTIVITY IS NOT ENHANCED BY PROCOLLAGEN C-PROTEINASE ENHANCER-1 (PCPE-1)
J. Biol. Chem.,
June 17, 2005;
280(24):
22616 - 22623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Gonzalez, C. C. Reed, G. Bix, J. Fu, Y. Zhang, B. Gopalakrishnan, D. S. Greenspan, and R. V. Iozzo
BMP-1/Tolloid-like Metalloproteases Process Endorepellin, the Angiostatic C-terminal Fragment of Perlecan
J. Biol. Chem.,
February 25, 2005;
280(8):
7080 - 7087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Brittingham, M. Colombo, H. Ito, A. Steplewski, D. E. Birk, J. Uitto, and A. Fertala
Single Amino Acid Substitutions in Procollagen VII Affect Early Stages of Assembly of Anchoring Fibrils
J. Biol. Chem.,
January 7, 2005;
280(1):
191 - 198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Garrigue-Antar, V. Francois, and K. E. Kadler
Deletion of Epidermal Growth Factor-like Domains Converts Mammalian Tolloid into a Chordinase and Effective Procollagen C-proteinase
J. Biol. Chem.,
November 26, 2004;
279(48):
49835 - 49841.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ge, N.-S. Seo, X. Liang, D. R. Hopkins, M. Hook, and D. S. Greenspan
Bone Morphogenetic Protein-1/Tolloid-related Metalloproteinases Process Osteoglycin and Enhance Its Ability to Regulate Collagen Fibrillogenesis
J. Biol. Chem.,
October 1, 2004;
279(40):
41626 - 41633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kansra, S. W. Stoll, J. L. Johnson, and J. T. Elder
Autocrine Extracellular Signal-regulated Kinase (ERK) Activation in Normal Human Keratinocytes: Metalloproteinase-mediated Release of Amphiregulin Triggers Signaling from ErbB1 to ERK
Mol. Biol. Cell,
September 1, 2004;
15(9):
4299 - 4309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Gopalakrishnan, W.-M. Wang, and D. S. Greenspan
Biosynthetic Processing of the Pro-{alpha}1(V)Pro-{alpha}2(V)Pro-{alpha}3(V) Procollagen Heterotrimer
J. Biol. Chem.,
July 16, 2004;
279(29):
30904 - 30912.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. KJAeR
Role of Extracellular Matrix in Adaptation of Tendon and Skeletal Muscle to Mechanical Loading
Physiol Rev,
April 1, 2004;
84(2):
649 - 698.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Steiglitz, M. Ayala, K. Narayanan, A. George, and D. S. Greenspan
Bone Morphogenetic Protein-1/Tolloid-like Proteinases Process Dentin Matrix Protein-1
J. Biol. Chem.,
January 9, 2004;
279(2):
980 - 986.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. N. Pappano, B. M. Steiglitz, I. C. Scott, D. R. Keene, and D. S. Greenspan
Use of Bmp1/Tll1 Doubly Homozygous Null Mice and Proteomics To Identify and Validate In Vivo Substrates of Bone Morphogenetic Protein 1/Tolloid-Like Metalloproteinases
Mol. Cell. Biol.,
July 1, 2003;
23(13):
4428 - 4438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-M. Wang, S. Lee, B. M. Steiglitz, I. C. Scott, C. C. Lebares, M. L. Allen, M. C. Brenner, K. Takahara, and D. S. Greenspan
Transforming Growth Factor-{beta} Induces Secretion of Activated ADAMTS-2: A PROCOLLAGEN III N-PROTEINASE
J. Biol. Chem.,
May 23, 2003;
278(21):
19549 - 19557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Hartigan, L. Garrigue-Antar, and K. E. Kadler
Bone Morphogenetic Protein-1 (BMP-1). IDENTIFICATION OF THE MINIMAL DOMAIN STRUCTURE FOR PROCOLLAGEN C-PROTEINASE ACTIVITY
J. Biol. Chem.,
May 9, 2003;
278(20):
18045 - 18049.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Leighton and K. E. Kadler
Paired Basic/Furin-like Proprotein Convertase Cleavage of Pro-BMP-1 in the trans-Golgi Network
J. Biol. Chem.,
May 9, 2003;
278(20):
18478 - 18484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Veitch, P. Nokelainen, K. A. McGowan, T.-T. Nguyen, N. E. Nguyen, R. Stephenson, W. N. Pappano, D. R. Keene, S. M. Spong, D. S. Greenspan, et al.
Mammalian Tolloid Metalloproteinase, and Not Matrix Metalloprotease 2 or Membrane Type 1 Metalloprotease, Processes Laminin-5 in Keratinocytes and Skin
J. Biol. Chem.,
April 25, 2003;
278(18):
15661 - 15668.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bernocco, B. M. Steiglitz, D. I. Svergun, M. V. Petoukhov, F. Ruggiero, S. Ricard-Blum, C. Ebel, C. Geourjon, G. Deleage, B. Font, et al.
Low Resolution Structure Determination Shows Procollagen C-Proteinase Enhancer to be an Elongated Multidomain Glycoprotein
J. Biol. Chem.,
February 21, 2003;
278(9):
7199 - 7205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Garrigue-Antar, N. Hartigan, and K. E. Kadler
Post-translational Modification of Bone Morphogenetic Protein-1 Is Required for Secretion and Stability of the Protein
J. Biol. Chem.,
November 1, 2002;
277(45):
43327 - 43334.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|